Skip to main content

Advertisement

Table 4 Health characteristics of schoolchildren successfully retraced (i.e. pre and post treatment-n = 853)

From: The impact of single versus mixed schistosome species infections on liver, spleen and bladder morbidity within Malian children pre- and post-praziquantel treatment

  Baseline Post-treatment
  Bamako Koulikoro Ségou Bamako Koulikoro Ségou
  (n = 273) (n = 153) (n = 427) (n = 273) (n = 153) (n = 427)
Parasitology
% Uninfected 45.05 (< 0.001)a 14.38 (< 0.001)b 8.90 (< 0.001)c 64.10 (< 0.001)d ** 32.68 (0.010)e ** 40.05 (< 0.001)f **
% Infected with S. haematobium 43.96 (< 0.001)a 3.92 (< 0.001)b 57.38 (< 0.001) c 26.37 (< 0.001)d ** 5.23 (< 0.001)e 35.36 (0.011) f **
% Infected with S. mansoni 1.10 (< 0.001)a 24.84 (< 0.001)b 4.22 (0.007)c 4.03 (< 0.001)d ** 40.52 (< 0.001)e ** 14.05 (< 0.001)f **
% Co-infected 9.89 (< 0.001)a 56.86 (< 0.001)b 29.51 (< 0.001)c 5.49 (< 0.001)d ** 21.57 (0.002)e ** 10.54 (0.013) f **
% Heavy S. haematobium infections 13.19 (0.040) a 7.19 (< 0.001) b 39.58 (< 0.001) 2.20 (0.161) c ** 0.65 (< 0.001) e ** 7.73 (< 0.001) f **
% Heavy S. mansoni infections 0.73 (< 0.001) 22.88 (0.005) 12.41 (< 0.001) 0.00 (< 0.001) 10.46 (0.003) ** 2.81 (< 0.001) **
Liver Pathology as assessed by ultrasound (US) examination
% with abnormal liver image patterns 0.37 (0.316)a 0.00 (< 0.001)b 12.18 (< 0.001)c 0.37 (0.316)d 0.00 (< 0.001)e 12.88 (< 0.001)f
% with portal hypertension (as determined by positive PVD scores) 0.73 (0.585)a 1.31 (< 0.001)b 9.60 (< 0.001)c 5.49 (0.013)d ** 13.07 (0.076)e ** 7.73 (0.237)f
% with hepatomegaly (as determined by positive PSL scores from US) 0.37 (0.701)a 0.65 (0.085)b 2.34 (0.085)c 0.00 (0.316)d 0.65 (0.545)e 0.23 (0.317)f **
Liver + spleen pathology as assessed by clinical examination
% with hepatomegaly as assessed by MSL>2 cm 0.00 (0.316)a 0.65 (< 0.001)b 9.84 (< 0.001)c 0.00 (0.080)d 1.96 (0.291)e 0.70 (0.082)f **
% with hepatomegaly as assessed by MCL>2 cm 0.00 (0.316)a 0.65 (< 0.001)b 8.67 (< 0.001)c 0.00 (0.080)d 1.96 (0.291)e 0.70 (0.082)f **
% with splenomegaly as assessed by MCL>2 cm 0.73 (< 0.001)a 12.42 (< 0.001)b 27.17 (< 0.001)c 0.00 (0.023)d 3.27 (0.009)e ** 8.43 (< 0.001)f **
% with splenomegaly as assessed by MAL>2 cm 0.73 (< 0.001)a 8.50 (< 0.001)b 25.06 (< 0.001)c 0.00 (0.043)d 2.61 (0.010)e ** 7.26 (< 0.001)f **
Bladder Pathology as assessed by US examination
Bladder pathology (as determined by positive global scores from US) 8.42 (0.194)a 5.23 (< 0.001)b 22.95 (< 0.001)c 22.34 (0.057)d ** 15.03 (< 0.001)e ** 3.98 (< 0.001)f **
  1. ap-values comparing proportions reported between Bamako and Koulikoro at baseline in parentheses; b p-values comparing proportions reported between Koulikoro and Ségou at baseline in parentheses; c p-values comparing proportions reported between Bamako and Ségou at baseline in parentheses; d p-values comparing proportions reported between Bamako and Koulikoro at follow-up in parentheses; e p-values comparing proportions reported between Koulikoro and Ségou at follow-up in parentheses; f p-values comparing proportions reported between Bamako and Ségou at follow-up in parentheses; ** significant differences at α = 0.05 between baseline and post treatment paired proportions as indicated by McNemar's test
  2. US, ultrasound; PVD, portal vain diameters; PSL, parasternal line; MSL, mid-sternal line; MCL, mid-clavicular line; MAL, mid-axillary line